Molecular Partners AG ADR Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)0.79 Intrinsic Value $5.46median of 2 methodsbased on filings through 30 Jun 2025 Market Price $3.95Price as of 30 Sep 2026 UndervaluedIntrinsic value is 38% above the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $151.3M Enterprise Value $72.3M Shares Outstanding 37.3M diluted Next Earnings Date29 Oct 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Molecular Partners AG is a clinical-stage pioneer of DARPin (Designed Ankyrin Repeat Protein) therapeutics, a novel class of custom-built protein drugs. The company's investment thesis centers on its transition into a leading targeted radiopharmaceutical player, specifically through its high-potential Radio-DARPin platform. Its lead candidate, MP0712 (targeting DLL3), is co-developed with Orano Med and has entered a Phase 1/2a trial in the US. DARPins offer unique advantages over traditional antibodies and peptides, including rapid tumor localization, deep penetration, and fast systemic clearance, which minimizes off-target radiation to healthy organs like the kidneys. Backed by a robust cash runway extending into late 2027 and strategic partnerships, Molecular Partners is well-positioned to capture significant valuation inflection points as clinical data readouts emerge in 2026. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$3.71 Mean target$10.93 High · most bullish analyst$16.77 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario The bear case reflects potential clinical setbacks, such as unexpected safety signals (e.g., severe off-target radiation or dose-limiting toxicities) in the MP0712 trial, or delays in clinical site activation. Slow patient recruitment or failure to advance MP0726 into the clinic in 2026 would compress the valuation. With no near-term commercial revenues, any clinical delay would accelerate cash burn and force a highly dilutive capital raise before late 2027. Base CaseCentral scenario The base case assumes steady clinical execution of the MP0712 Phase 1/2a trial with initial safety and imaging data in 2026 confirming favorable biodistribution and tumor uptake. It also assumes the successful IND filing and initiation of first-in-human imaging for the second Radio-DARPin candidate, MP0726, in H2 2026. The company maintains its cash runway into late 2027, supported by disciplined R&D spending. Bull CaseUpside scenario Successful clinical validation of the lead Radio-DARPin candidate MP0712 in Phase 1/2a trials, demonstrating favorable safety and efficacy in SCLC, which unlocks the broader isotope-agnostic Radio-DARPin platform and triggers milestone payments from strategic partners. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |